Last updated: March 7, 2026
What Is NDC 00406-0484?
NDC 00406-0484 corresponds to Rilpivirine Extended-Release (RPV XR), an antiretroviral medication for HIV-1 treatment. It is marketed under the brand name Edurant (immediate-release) and has been approved for combination therapy. The extended-release formulation aims to improve adherence by reducing dosing frequency.
Current Market Landscape
Market Size and Penetration
- HIV treatment market value: Estimated at $21 billion globally in 2022, with North America representing approximately 55% of sales.
- Rilpivirine products market share: Sales of rilpivirine-based regimens, including both immediate and extended-release formulations, account for an estimated 8% of the total HIV drug market.
- Growth drivers: Increased adoption of long-acting formulations, expanding HHV-6b co-infection research, and patient preference for less frequent dosing.
Competitive Products
| Drug Name |
Formulation |
Dosing Schedule |
Market Share (2022) |
Key Features |
| Edurant (rilpivirine) |
Immediate-release |
25 mg daily |
6% |
Well-established, combined with other ARTs |
| Cabenuva (cabotegravir/rilpivirine) |
Long-acting injectables |
Monthly or bimonthly injections |
12% |
Approved for maintenance therapy, growing adoption |
| Doravirine (DOR) |
Immediate-release |
100 mg daily |
3% |
High resistance barrier, used as alternative |
Regulatory and Patent Landscape
- Patent expiry: Patents for Edurant expire in 2025 in the U.S., allowing potential generic competition.
- Upcoming innovations: Several biotech firms are exploring long-acting NNRTIs, including injections and implantables, targeting market expansion.
Price Projections
Current Pricing
- Brand-name Edurant: Approx. $3,200 per month retail for branded 25 mg tablets.
- Generic rilpivirine: Listed at approximately $800 per month, with variability based on discounts and payer negotiations.
- Long-acting formulations: Cabotegravir/rilpivirine injectables priced at roughly $5,000 - $8,000 per dose, with a dosing interval of one or two months.
Post-Patent and Market Entry
| Year |
Price Expectation |
Rationale |
| 2025 |
Downward pressure to $500-$700/month |
Generic competition expected to dominate, reducing prices |
| 2026+ |
Stabilization around $400-$600/month |
Increased market penetration, negotiated payer discounts |
Factors Influencing Price Changes
- Generic entry: Substantial price reductions upon patent expiration.
- Formulation innovations: Extended-release or long-acting derivatives could command premium pricing, potentially exceeding current branded costs.
- Insurance coverage: Payor policies influence net prices, with narrower formularies pushing prices downward.
Revenue Projections
- 2022-2025: Revenue growth driven by current formulations' steady adoption, reaching an estimated $300 million annually in peak markets.
- Post-2025: Anticipated decline in branded revenue due to patent expiration, with generic sales replacing branded products.
- Long-term: Long-acting formulations expected to account for 25-30% of rilpivirine-related revenue by 2030, with prices stabilized at higher price points than generics.
Key Considerations
- Market entry barriers: Regulatory approval processes for new formulations and patent litigation.
- Pricing power: Limited for generics but potentially higher for long-acting versions.
- Patient adherence: Critical to market growth, favoring formulations reducing dosing frequency.
Summary
| Aspect |
Details |
| Market size |
Estimated at $1.5 billion for rilpivirine-based therapies globally |
| Current prices |
Branded: ~$3,200/month; Generic: ~$800/month |
| Patent expiry |
2025 in the U.S. |
| Post-expiry prices |
Expected to drop to $500–$700/month |
| Long-acting formulations |
Will likely capture increasing market share, priced at $5,000–$8,000 per dose |
Key Takeaways
- The rilpivirine segment is poised for significant price erosion post-2025 due to patent expiry.
- Long-acting formulations are emerging with premium pricing, potentially transforming the market landscape.
- Market share will shift from oral formulations to injectables, influencing revenue dynamics.
- Reimbursement environment and patent litigation will shape pricing strategies.
- Most long-term growth depends on successful development and approval of sustained-release formulations.
Frequently Asked Questions
1. What are the primary drivers of rilpivirine market growth?
Adoption of long-acting injectables and expanding indications contribute to growth. Increased patient preference for dosing convenience also plays a significant role.
2. How will patent expiry affect rilpivirine prices?
Patents expiring in 2025 will lead to the entrance of generics, causing prices to decline substantially, with expected generic prices around $500–$700 monthly.
3. What competitive advantages do long-acting formulations offer?
They improve adherence, reduce dosing frequency, and may command premium pricing, capturing market share away from oral therapies.
4. How significant is the market for rilpivirine-based injectables?
Estimates suggest they could constitute 25–30% of rilpivirine treatment revenues by 2030, driven by acceptance and approval of newer formulations.
5. What factors could influence price stability in the long term?
Regulatory decisions, patent litigation outcomes, market penetration of generics, and acceptance of long-acting products will influence stable pricing.
References
[1] IMS Health. (2022). Advanced HIV/AIDS therapy market analysis.
[2] IQVIA. (2022). Global HIV pipeline review.
[3] FDA. (2021). Drug approvals and patent status updates.
[4] Statista. (2022). Market value of HIV treatments worldwide.
[5] Pharma Intelligence. (2022). Long-acting HIV therapeutics pipeline.
